Opna Bio
Latest round
- Series A
Last raised
- Nov 2022
Total raised
- $38M
Investors
- 3
About Opna Bio
Based in Switzerland, Opna Bio SA is a clinical-stage biopharmaceutical company that specializes in the development of cancer therapy medications. Gideon Bollag (CEO), Joseph Schlessinger, and Douglas Hanahan are the co-founders of the company. As of 2022, the company also has an office in the US. The company provides its lead clinical product, OPN-2853, a bromo- and extra-terminal (BET) domain inhibitor, which is in Phase 1/2 trial with ruxolitinib (Jakafi®) in myelofibrosis, a chronic bone marrow disorder. The firm’s other pipeline programmes include OPN-7486, OPN-6602, OPN-CD73, OPN-TEAD, and OPN-FMRP.
Who invested in Opna Bio
3 investors across 1 round
See all investors in Opna Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 21, 2022
Amount
$38M
Investors
Questions about Opna Bio
Who invested in Opna Bio?
Opna Bio has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Opna Bio raised?
Opna Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Opna Bio last raise money?
Opna Bio's most recent round on record is a Series A, in Nov 2022.
What does Opna Bio do?
Based in Switzerland, Opna Bio SA is a clinical-stage biopharmaceutical company that specializes in the development of cancer therapy medications.
Where is Opna Bio headquartered?
Opna Bio is headquartered in Switzerland.
Which VCs invest in companies like Opna Bio?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Opna Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Opna Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.